Medtronic Inc. (NYSE:MDT) is sending its Contour 3D annuloplasty ring out into the world.
The Fridley, Minn.-based medical device giant’s latest device is designed to treat tricuspid valve disease, in which the valve between the heart’s right atrium and the right ventricle doesn’t function properly. The ring slips over the three-leaflet valve to restore its function.
Medtronic won 510(k) clearance for the device in August 2010, the same month it closed a $370 million for ATS Medical Inc.
Shawn Monaghan, vice president of surgical-based therapies for Medtronic’s structural heart business, said the company’s portfolio of tricuspid valve repair products "was made possible in part" by the ATS acquisition.
